Kyndryl Q1 FY2027: Net Loss of $55M, Revenue Down 3%, Material Weaknesses Persist
KD sits 36% above its 52-week low of $10.1 on elevated volume (2.1× avg).
Summary
Kyndryl posted a Q1 FY2027 net loss of $55 million on revenue of $3.62 billion, down 3% year-over-year, including $152 million in restructuring charges. Material weaknesses in internal controls and an SEC investigation remain unresolved.
Key Events · Earnings and Guidance · KD
-
Q1 FY2027 Net Loss of $55M
A net loss of $55 million, or $0.25 per share, replaced the prior-year quarter's $56 million profit, as $152 million in workforce rebalancing charges and a $38 million impairment weighed on results.
-
Revenue Declines 3% to $3.62B
Revenue slipped 3% year-over-year to $3.618 billion, with declines in Japan, Principal Markets, and Strategic Markets partially offset by 5% growth in the United States.
-
Workforce Rebalancing Charges of $152M
A new restructuring program, expected to cost $200 million, recorded $152 million in Q1. Once complete, management anticipates annual savings of $400–$500 million.
-
Material Weaknesses and SEC Investigation Ongoing
Unremediated material weaknesses in internal control over financial reporting persist, alongside an ongoing SEC investigation into cash management practices and a pending securities class action lawsuit.
Analysis · KD · Technology
A $152 million workforce rebalancing charge and a 3% revenue decline pushed Kyndryl to a $55 million net loss in Q1 FY2027, reversing the prior year's $56 million profit. The quarter also highlights persistent governance concerns, with unremediated material weaknesses in internal controls and an ongoing SEC investigation into cash management practices. New leadership appointments—a CFO effective August 6, 2026, and a General Counsel starting July 6, 2026—signal efforts to address these challenges, but the results underscore the operational and oversight hurdles ahead.
At the time of this filing, KD was trading at $13.75 on NYSE in the Technology sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $10.10 to $33.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.